SCHEMBL5947435

SCHEMBL5947435

FC(F)(F)c1cccc(CCNCc2cccc(Nc3ccccn3)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.54
▸ KDM4E B2RXH2 4/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ CTSC P53634 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ NR3C2 P08235 1/20 0.47
▸ AURKA O14965 5/20 0.46
▸ SCN8A Q9UQD0 1/20 0.45
▸ SLC2A1 P11166 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ GPR52 Q9Y2T5 2/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947182 0.85 MEN1 (0.58) ROCK1KDM4EMEN1KMT2ATDP1
SCHEMBL5947838 0.83 ROCK1 (0.57) ROCK1KDM4EMEN1KMT2ACTSC
SCHEMBL5947459 0.83 CYP1A2 (0.50) KDM4EAURKAMAPTMAPK1LMNA
SCHEMBL5947690 0.81 KIF11 (0.64) ROCK1KDM4EMEN1KMT2ACTSC
SCHEMBL4656669 0.80 CTSC (0.65) KDM4EMEN1KMT2ACTSCTDP1
SCHEMBL30128849 0.80 CTSC (0.65) KDM4EMEN1KMT2ACTSCTDP1
SCHEMBL27595877 0.80 ROCK1 (0.56) ROCK1KDM4EMEN1KMT2ATDP1
SCHEMBL22579188 0.78 KDM4E (0.63) ROCK1KDM4EMEN1KMT2ATDP1
SCHEMBL5947177 0.77 KDM4E (0.58) ROCK1KDM4EMEN1KMT2ATDP1
SCHEMBL19892582 0.77 FABP1 (0.61) ROCK1KDM4ENR3C2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B ROCK1 4112/4885KDM4E 1970/4885MEN1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback